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Abstract: The effects of an intravitreal or subretinal injection of soluble or aggregated forms 
of Aβ1–42 on retinal nestin-immunoreactivity (-IR) and glial ﬁ  brillary acidic protein (GFAP)-IR 
in astrocytes and Müller glial cells and the integrity of the blood-retinal barrier (BRB) were 
tested in the in vivo rat vitreal-retinal model. Retinas were exposed for 1, 2, 3, 5 or 30 days. 
We present novel data demonstrating that aggregated Aβ1–42 up-regulates nestin-IR in astrocytes 
and Müller cells, with a graded response directly related to the length of pre-injection aggregation 
time. Similar results were obtained with GFAP-IR, but the signal was weaker. An intravitreal 
injection of aggregated Aβ1–42 led to VEGF-IR up-regulation, particularly in the GCL and to 
a lesser extent in the INL. VEGFR1-IR (Flt1) was also increased, particularly in Müller cells 
and this was accompanied by marked leakage of albumin into the retinal parenchyma of the 
injected eye, but not in the contralateral eye.
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Introduction
The histopathological hallmarks of Alzheimer’s disease (AD) are extracellular amyloid 
plaques and intracellular neuroﬁ  brillary tangles. The major component of amyloid 
plaques is amyloid-β (Aβ), a peptide formed by the cleavage of the amyloid precursor 
protein (APP) and which has previously been shown to be neurotoxic (Jen et al 1998; 
Abramov et al 2004; Walsh et al 2002; Walsh et al 2005). The relevance of Aβ1–42 in 
AD is supported by familial forms of AD in which most of the missense mutations 
in the genes encoding APP and presenilin increase the production of Aβ1–42. There 
is evidence that Aβ also opens the blood-brain barrier (BBB) (Preston et al 1998; 
Kalaria and Hedera 1995; Berzin et al 2000; Abbott et al 2006; Marco and Skaper 
2006; Dickstein et al 2006).
The rodent retinal-vitreal model of Aβ toxicity as investigated in this laboratory (Jen 
et al 1998; Walsh et al 2002) offers great potential to monitor the effects of amyloid-β 
(Aβ) on different cell types of the CNS in vivo. It is an easily accessible self-contained 
and well-delineated, uniform CNS system in which the state of aggregation of amyloid 
can be monitored over time and correlated with observed pathological changes. Our 
previous studies using the Bachem (UK) peptides have implicated highly-aggregated 
ﬁ  brillar species forms of Aβ as causing neuronal death on injection (Jen et al 1998; 
Walsh et al 2002; Walsh et al 2005). However, in recent years it has been suggested 
that soluble forms of Aβ, eg, monomers (Selkoe 2002; Soden et al 2004), oligomers 
(a.k.a. “Aβ-Derived Diffusible Ligands, ADDLs”) (Chromy et al 2003), or small 
preﬁ  brillar entities known as “protoﬁ  brils” (Nilsberth et al 2001; Ye et al 2004) may 
be important in AD, and display a variety of toxic effects in vitro or on certain in vivo 
parameters.Clinical Ophthalmology 2008:2(4) 802
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One important reason for continuing uncertainty about 
the nature of the actual pathological Aβ species is that the 
physical aggregation state of Aβ preparations is labile and 
depends on numerous factors, including: age or conditions 
of the animals, sources of the peptides, batch variation 
in the peptide manufactured within a given company, 
concentration, temperature, period of incubation, ionic 
constituents, pH and storage conditions. In addition, 
aggregation state is expected to change radically during 
experimental conditions, as local conditions and exposure 
to cells and cellular membranes, which themselves modify 
aggregation, will vary markedly.
Our previous studies found very signiﬁ  cant glial cell 
immunoreactivity and increased DNA fragmentation in 
photoreceptor cells and interneurons after 2 days of exposure 
with ﬁ  brillar Aβ (Jen et al 1998; Walsh et al 2002), and 
atrophy and loss of neurons in the ganglion cell layer (GCL) 
after 5 months (Walsh et al 2005).
This paper describes the effects of Aβ on glial cells 
in the eye of the rat and on blood-retinal barrier (BRB) 
integrity. Using this in vivo retinal-vitreal model, we found 
that the aggregated form of Aβ1–42, but not the soluble form, 
signiﬁ  cantly up-regulated nestin immunoreactivity (IR) and 
GFAP-IR in retinal astrocytes and Müller glia cells. This is 
the ﬁ  rst paper to report that nestin is up-regulated in retinal 
glia in the presence of Aβ1–42. We also present evidence 
that intravitreal injection of Aβ1–42 results in an increase 
in the immunoreactivities of vascular endothelial growth 
factor (VEGF-IR) and VEGF receptor-1 (VEGFR1-IR). 
We also detected perivascular albumin staining of the retinal 
parenchyma, implying that intravitreal injection of Aβ1–42 
results in breakdown of the BRB.
Methods
Chemicals
Amyloid-β1–42 (Aβ1–42) and Aβ42–1 from California Peptide 
and Bachem; lipopolysaccharide (LPS, Sigma, Poole, UK).
Primary antibodies
Nestin monoclonal antibody (1:1000, Chemicon, Millipore 
UK Ltd); glial ﬁ  brillary acidic protein (GFAP) polyclonal 
antibody (1:1000, Sigma, Poole, UK); monoclonal anti-rat 
endothelial cell antigen 1 (RECA1, 1:200, Abcam, Cambridge, 
UK); polyclonal rabbit anti-vascular endothelial growth factor 
(VEGF); mouse monoclonal VEGF receptor 1 (VEGFR1, 
Abcam, Cambridge, UK); sheep polyclonal anti-rat albumin 
(1:100, ab20742, Abcam, Cambridge, UK); sheep polyclonal 
to rat albumin (1:100, Abcam, Cambridge, UK).
Secondary antibodies
Streptavidin-alexa 488 (1:1000); Cy3-conjugated 
Afﬁ  niPure IgG (H+L) (1:500, Jackson ImmunoResearch 
Europe, Ltd).
Animals
Adult female Sprague Dawley rats (weighing 150–350 g).
Treatments
The effects of a single 3 μL injection of Aβ1–42 (2 nmol 
in 3 μL PBS, or 5 nmol in 3 μL PBS) on retinal nestin-IR 
and GFAP-IR were compared with those of a recognized 
inﬂ  ammatory agent, lipopolysaccharide (LPS). Two working 
solutions of LPS were used: 10 μg/mL and 50 μg/mL. The 
total volume injected into the eye was always 3 μL for all 
treatments. The reverse form of Aβ (Aβ42–1) was tested as a 
non-active form of the peptide. The effects of vehicle only 
(ie, PBS) were also assessed. Injections were administered 
intravitreally or subretinally to assess any differences in 
responses to the site of injection. Aβ was injected into the 
left eye, the right eye being used as a contralateral control.
Aβ preparation
Aggregated Aβ was prepared by dissolving Aβ in phosphate 
buffered saline (PBS) and sonicating it for 1 minute to give 
a concentration of either 2 nmol/3 μL or 5 nmol/3 μL. It was 
then incubated for 4 or 8 days at 37 oC to aggregate the 
peptide. Soluble Aβ peptide was produced by dissolving Aβ in 
phosphate buffered saline (PBS, pH 7.4) and sonicating it for 
1 minute and freezing it at −20 °C without any pre-injection 
aggregation phase until ready for use. Although referred to 
as “soluble Aβ”, it is unlikely that such a preparation consists 
purely of soluble Aβ. In all probability it comprises a mixture 
of soluble and oligomeric forms and has been referred to as 
soluble Aβ throughout this paper for ease of reference. It was 
noted that the viscosity of the Aβ solution increased with the 
inclusion of a pre-injection aggregation stage. Again, for ease 
of reference, we refer to Aβ sources that underwent a 4-day 
or 8-day incubation at 37 oC prior to injection as aggregated 
(4-day) Aβ and aggregated (8-day) Aβ respectively.
Post-injection time points
1 day, 2 days, 3 days, 5 days, 30 days.
Animals were allocated to the following treatment groups:
I.   Exposure to a single intravitreal injection of 2 nmol Aβ1–42 
in 3 μl PBS for 1, 2 and 3 days.
  Aggregated (4-day pre-injection aggregation period) 
Aβ1–42 (2 nmol/3 μL PBS) was injected into the left eyes Clinical Ophthalmology 2008:2(4) 803
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of 9 rats. The rats were split into groups of three and 
were perfused following 1, 2 or 3 days of exposure to 
Aβ (see below).
II. Exposure to 5 nmol Aβ in 3 μl PBS
  2-day exposure: (1) Aggregated (8-day pre-injection 
aggregation period) Aβ1–42 injected intravitreally 
(abbreviation, aggr (8d) Aβ iv), n = 5; (2) aggregated 
(8-day pre-injection aggregation period) “reverse” Aβ 
(ie, Aβ42–1) injected intravitreally (abbreviation, aggr (8d) 
Rev Aβ iv), n = 3; (3) aggregated (4-day pre-injection 
aggregation period) Aβ1–42 injected intravitreally 
(abbreviation, aggr (4d) Aβ iv), n = 8; (4) aggregated 
(4-day pre-injection aggregation period) “reverse” 
Aβ (Aβ42–1) injected intravitreally (abbreviation, 
aggr (4d) Rev Aβ iv), n = 5; (5) Soluble Aβ1–42 
injected intravitreally (abbreviation, Sol Aβ iv), n = 4; 
(6) aggregated (4-day pre-injection aggregation period) 
Aβ1-42 injected sub-retinally (sr) (abbreviation, aggr (4d) 
Aβ sr), n = 3; (7) LPS (10 μg/mL) injected intravitreally 
(abbreviation, LPS(10)), n = 4; (8) LPS (50 μg/mL) 
injected intravitreally (abbreviation, LPS (50)), n = 4; 
(9) aggregated (4-day pre-injection aggregation period) 
Aβ1–42 plus LPS (50 μg/mL) injected sub-retinally 
(abbreviation, aggr (4d) Aβ1–42 + LPS(50) sr), n = 3; 
(10) Soluble Aβ1–42 + LPS (50) injected intravitreally 
(abbreviation, Sol Aβ + LPS (50) iv), n = 3; (11) PBS 
injected intravitreally (abbreviation, PBS iv), n = 5; 
(12) PBS injected subretinally (abbreviation, PBS sr), 
n = 3.
  5-day exposure: This applied to ﬂ  atmount preparations 
only to investigate if Aβ1–42 compromises the BRB. PBS 
(n = 3); Aβ1–42 1; Aβ42–1 (n = 5). This longer exposure time 
was chosen to investigate whether the effects of Aβ1–42 
on albumin leakage were lessened, sustained or even 
increased over a period greater than 2 days. The choice 
of time period was particularly inﬂ  uenced by a recent in 
vitro study on endothelial cells isolated from rat cerebral 
cortex (Marco and Skaper 2006). These workers found 
that the tight junction protein claudin-1 was maximally 
up-regulated and ZO-2 was maximally down-regulated 
after a 3-day exposure to Aβ1–42. Since this 3-day exposure 
time was the maximum time period that was investigated 
by these workers, we decided to extend the survival time 
by two days in our model since it was an in vivo system 
where the effects of Aβ on capillary endothelium might 
be different to that found in vitro.
 30-day  exposure: (1) Naïve = non-injected tissue (n = 4); 
(2) PBS = vehicle injection (n = 5); (3) Reverse = Aβ42–1 
control peptide (n = 3); (4) Aβ1–42 (California Peptide) 
(n = 7); (6) Aβ1–42 (Bachem) (n = 7).
All experimental procedures were carried out in 
accordance with the Animals (Scientiﬁ  c Procedures Act) 
1986. Animals were anesthetized using an intraperitoneal 
injection of a mixture of ketamine/xylazine (dosage, 0.25 mL 
per 100 g body weight). Before injection, some of the 
vitreous humor was removed to avoid increased intra-ocular 
pressure. Rats received a single unilateral intravitreal or 
subretinal 3 μL injection containing their assigned compound 
according to their treatment group. On completion of the 
treatment period, rats were anesthetized with Euthetal and 
then perfused with PBS followed by a 4% paraformaldehyde 
(PFA) solution. The treated (left) and untreated (right) eyes 
were removed and left overnight in a concentrated sucrose 
solution. Each pair of eyes was embedded in OCT solution, 
frozen in isopentane pre-cooled in liquid nitrogen and stored 
at −20 °C. OCT-embedded eyeballs were cut into sections 
20 μm thick and mounted onto SuperFrost® Plus gelatinized 
slides (VWR International).
Preparation of retinal ﬂ  atmounts
Eyeballs were post-ﬁ  xed in 4% PFA for 30 minutes to harden 
the retinal tissue. The eyeball was then suspended in PBS and, 
after removing the cornea and lens, the retina was carefully 
detached from the eyeball. Four radial cuts were made in the 
outer two-thirds of the retina at 90° to one another. The retina 
was placed on a SuperFrost® Plus slide.
Nissl staining
The cytoarchitecture and morphology of the retinal cells 
were visualized using Nissl staining. Retinal sections were 
immersed in a solution of 0.1% cresyl fast violet in water for 
1 minute at room temperature and then washed with water 
before being differentiated in diluted acetic acid. The sections 
were dehydrated by passing them through an alcohol ladder 
(70%, 90%, 95% and 100%), then cleared in xylene and 
mounted in DPX.
TUNEL staining
Retinal sections were tested for DNA fragmentation 
using Apoptag kits (Q-biogene, Hareﬁ  eld, UK) to deter-
mine terminal deoxynucleotidyl transferase dUTP end 
labelling (TUNEL). Retinal sections were permeabilized 
by post-fixing in pre-cooled ethanol:acetic acid (2:1) 
for 5 minutes at −20 °C and then rinsed twice in PBS. 
Endogenous peroxidises were quenched in 0.3% H2O2 for Clinical Ophthalmology 2008:2(4) 804
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5 minutes at room temperature. Sections were bathed in 
equilibration buffer for at least 10 seconds prior to their 
incubation with TdT enzyme for 1 hour at 37 °C after 
which stop/wash buffer was applied for 15 minutes to 
terminate the reaction. After rinsing in PBS, anti-dioxygenin 
peroxidise-conjugated antibody was added to each section 
and incubated for 30 minutes at room temperature. Sections 
were rinsed in PBS and bound antibodies were visualized 
with diaminobenzidine (DAB) peroxidise substrate kit 
(Vector, Peterborough, UK).
Immunohistochemistry (IHC)
Cryostat sections and flatmounts were processed 
for immunostaining using antibodies against nestin, 
GFAP, RECA1, VEGF, VEGFR-1, albumin. Nes-
tin, GFAP and VEGF were determined using the 
ABC-diaminobenzidine (DAB) method, whereas RECA1, 
VEGFR1 and albumin were determined using a double 
ﬂ  uorescence method.
Sections were washed in PBS/0.3% Triton X-100 
(Sigma, UK) and blocked in normal serum before addi-
tion of the primary antibody overnight. Sections were 
washed and incubated with biotinylated secondary antibody 
(Vector, Peterborough, UK) for 45 minutes followed by 
further washing and incubation in Vectastain Elite ABC 
kit for 45 minutes (Vector, Peterborough, UK). Staining 
was visualized using the DAB peroxidise substrate kit 
(Vector, Peterborough, UK). Sections were dehydrated in an 
increasing alcohol gradient, cleared in xylene and mounted 
with DPX.
Double immunoﬂ  uorescence RECA1 
and albumin: reagents
Anti-RECA-1, mouse monoclonal [HIS52] used at 1:200 in 
PBST (including 2% normal horse serum); Streptavidin-alexa 
488 used at 1:1000 in PBST; anti-rat albumin, sheep poly-
clonal used at 1:100 (cross reacts with mouse albumin). 
Cy™3-conjugated Afﬁ  niPure rabbit anti-sheep IgG (H + L), 
diluted 1:500 in PBST (keep wrapped in foil). Day 1. Sections 
were washed 3 × 5 minutes with 0.1% PBST and then incubated 
with 10% normal horse serum (NHS) for 30 minutes. The NHS 
was removed without rinsing, 200 μL of RECA1 antibody 
was added to each slide (except the negative control) and left 
to incubate overnight at room temperature. Day 2. Sections 
were washed 3 × 5 minutes with PBST and incubated with 
biotinylated horse anti-mouse (rat adsorbed) IgG (H + L), 
(dilution of 1:100) for 1 hour at room temperature. Sections 
were washed again 3 × 5 minutes with PBST and then incubated 
with streptavidin (SAV) 488, diluted 1:1000 in PBST for 1 hour 
at room temperature in the dark to avoid photo-bleaching. 
Sections were then washed 3 × 5 minutes with PBST and then 
incubated in 10% normal rabbit serum for 30 minutes at room 
temperature. Sections were then incubated overnight with 
abcam® sheep polyclonal to rat albumin, diluted 1:100 in PBST 
(containing 2% normal rabbit serum) at room temperature. 
Day 3. Sections were washed 3 × 5 minutes with PBST before 
being incubated with Cy™3-conjugated Afﬁ  niPure rabbit anti-
sheep IgG (H+L), diluted 1:500 in PBST. Sections were washed 
3 × 5 minutes with PBST. Finally, sections were mounted in 
Vectashield Mounting Medium with DAPI and sealed with nail 
varnish. They were then wrapped in foil and stored at 4 °C until 
ready to examine under the ﬂ  uorescent microscope.
Imaging
Image analysis of tissue sections was carried out using 
Image-Pro Plus 6.0 (Media Cybernetics Inc, Silver Spring, 
MD, USA). Images were captured using a Nikon Eclipse 50i 
Microscope and Nikon E1000M Fluorescence microscope. 
Sections were examined at × 20 magniﬁ  cation and scores 
assigned for 5 different retinal regions per section according 
to a 5-point scoring system (Table 1).
Nestin/GFAP scoring system
The degrees of nestin-IR and GFAP-IR were estimated using 
the scoring system depicted in Table 1.
Statistics
Nestin and GFAP scores were analysed to assess whether 
overall differences between groups were signiﬁ  cant using 
the one-way non-parametric ANOVA Kruskal-Wallis test. 
If signiﬁ  cant, the non-parametric Mann-Whitney test was 
Table 1 Nestin/GFAP scoring system based on extent of IHC 
staining
Score Description
0 Negligible staining
1 Müller cell endfeet region/GCL only
2 Müller cell endfeet region/GCL plus a few 
proximal processes
3 Müller cell endfeet plus many processes, but 
not extending to ONL
4 Müller cell endfeet plus processes throughout 
with some in the ONL
5 Müller cell endfeet plus lots of dark processes 
from GCL to outer margin of ONLClinical Ophthalmology 2008:2(4) 805
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used to determine if the difference between treatments was 
signiﬁ  cant. Results were expressed as mean values ± standard 
error of the mean (SEM). Differences between means were 
considered to be signiﬁ  cant at a level of probability less than 
0.05 (p  0.05).
Results
Nissl staining and TUNEL
We could not detect any signiﬁ  cant cell death in the form of 
pyknosis (by examining retinal sections stained with cresyl 
violet) or apoptosis (by TUNEL staining) in any of the treat-
ments 48 hours after injection (results not shown). However, 
injected eyes, 1 month post-injection displayed signiﬁ  cant 
retinal atrophy (p  0.001) relative to PBS controls and 
Aβ1–42 injection at 48-hour survival (See Watts et al 2008, 
in preparation). Many retinas were reduced to half normal 
thickness, with atrophy occurring mainly in the INL (reduced 
to 3–4 cells thick after 1 month, compared with 6–8 cells 
for naïve tissue), whereas the density of photoreceptors 
(ONL thickness) was largely preserved.
Nestin
Nestin is a type VI intermediate ﬁ  lament protein which is 
expressed abundantly in neuroepithelial stem cells in the 
early stages of embryogenesis and also in adult neural stem 
cells and neuroepithelial cells (Lendahl et al 1990). Once 
cells have differentiated, nestin tends to be down-regulated 
and to be replaced by other tissue-speciﬁ  c intermediate 
ﬁ  laments.
Up-regulation of nestin accompanies certain pathological 
conditions in the adult, such as in reactive astrocytes during 
the formation of glial scars after CNS injury (Clarke et al 
1994; Frisen et al 1995; Krum and Rosenstein 1999). This 
re-induction of nestin might also be indicative of cells 
undergoing de-differentiation (Chang et al 2007).
A. 2-day exposure
(i) Exposure to aggregated (4 days) Aβ1–42 
(2 nmol/3 μL)
There is a signiﬁ  cant up-regulation of nestin with time in retinas 
exposed to a single intravitreal injection of aggregated (4 days) 
Aβ1–42 (2 nmol/3 μL PBS) (Figure 1a). This up-regulation 
increased linearly every 24 hours for the 3-day period 
investigated (Figure 1b). The goodness-of-ﬁ  t, r2 = 0.98; and 
p = 0.0119. In contrast, there was no statistically signiﬁ  cant 
linear relationship for GFAP up-regulation with time after 
a single intravitreal injection of aggregated (4 days) Aβ1–42 
(2 nmol/3 μL) (results not shown).
In order to maximize the responses of nestin-IR and 
GFAP-IR, all subsequent injections delivered 5 nmol 
Aβ/3 μL PBS which gave clear responses for both nestin 
and GFAP.
(ii) Effect of length of pre-injection incubation time
A single intravitreal injection of aggregated (4 days) 
Aβ1–42 iv led to a marked up-regulation of nestin-IR within 
the processes of Müller glial cells (Figure 2). Figure 3 shows 
the equivalent responses in 3 different regions of the retina in 
eyes injected intravitreally with 8-day pre-aggregated Aβ1–42. 
Visually, the strength of response of 8-day pre-aggregated 
Aβ1–42 was not just extensive, throughout all neural retinal 
layers, but the staining of individual Müller cell processes 
appeared much thicker than that of 4-day pre-aggregated 
Aβ1–42 (compare Figure 3a with nestin photomicrographs in 
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Figure 1 (a) Retinal nestin response 1, 2 and 3 days after a single intravitreal injection 
of 2 nmol/3 μL aggregated (4d) Aβ1-42. Each bar represents the mean ± SEM. (b) Linear 
trend of nestin response with time. Dotted lines represent 95% conﬁ  dence limits.Clinical Ophthalmology 2008:2(4) 806
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Figure 2). Since nestin is an intermediate ﬁ  lament protein 
in Müller glia cells, it could be acting as scaffolding for 
increased rigidity of the retina, especially if there has been 
loss of neuronal cells.
Nestin was very signiﬁ  cantly (p  0.01) up-regulated 2 days 
after a single intravitreal injection of aggregated (4 days) Aβ1–42 
when compared with a single intravitreal injection of PBS 
(Figure 6a). Furthermore, a single intravitreal injection of 
aggregated (8 days) Aβ1–42 up-regulated nestin-IR to a signiﬁ  -
cantly higher level incrementally (p  0.05) when compared 
with that of a single intravitreal injection of aggregated 
(4 days) Aβ1–42 (Figure 4a).
A single intravitreal injection of soluble Aβ1–42 did not 
signiﬁ  cantly up-regulate nestin when compared with an 
equivalent injection of PBS alone (Figure 4a). In contrast, 
there was a very signiﬁ  cant difference between a single 
subretinal injection of aggregated (4 days) Aβ1–42 and a 
single subretinal injection of PBS (Figure 4a). The fact that 
a single intravitreal aggregated (8 days) Aβ1–42 resulted in a 
further signiﬁ  cant (p  0.05) incremental up-regulation in 
nestin (Figure 6a) conﬁ  rmed that aggregated forms of Aβ1–42 
appear to be more potent in eliciting a response in nestin-IR 
than the soluble form.
(iii) Site of injection
The difference in response between a single intravitreal 
injection of aggregated (4d) Aβ1–42 and that of a single 
subretinal injection of aggregated (4 days) Aβ1–42 was not 
signiﬁ  cant following a 2-day exposure period (Figure 4a). 
Thus, there appears to be no site-of-injection polarity in the 
response of retinal nestin.
(iv) Source of Aβ
Aβ1–42 peptides from California Peptide and Bachem were 
prepared in an identical manner on the same day. Single intra-
vitreal injections of aggregated Aβ1–42 (5 nmol/3 μL) were 
administered to the left eyes of two different groups (n = 7) 
and the trial was terminated 1 month later. The up-regulation 
of nestin was compared between the two different groups to 
see if the source of Aβ1–42 affected the response. There was 
GFAP Nestin
PBS 
Aβ1−42
Figure 2 Retinal nestin and GFAP response 48 hours after a single intravitreal injection of PBS (vehicle) or Aβ1-42 (5 nmol in 3 μL) pre-aggregated for 4 days. Note that 
both markers show marked up-regulation in retinas exposed to Aβ1-42 compared with those retinas exposed to PBS. Each panel corresponds to a 20 μm thick section. 
Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bar corresponds to 100 μm.Clinical Ophthalmology 2008:2(4) 807
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(b) GFAP
Injected
Injected
Non-injected
Non-injected
(a) Nestin
Optic C1 C2
Figure 3 Immunohistochemical retinal response of (a) nestin and (b) GFAP 2 days after a single injection of Aβ1-42 (5 nmol in 3 μl PBS) pre-aggregated for 8 days. Note the 
smaller contralateral response in the non-injected eye. Each panel corresponds to a 20 μm section of retinal tissue. C1, Optic, and C2 correspond to 3 representative regions 
of the neural retina equidistant from one another. Scale bar, 100 μm.
no signiﬁ  cant difference in nestin up-regulation between 
California Peptide and Bachem sources of aggregated 
(8 days) Aβ1–42 (Figure 4d).
(v) LPS
Single intravitreal injections of 10 μg/mL LPS did not cause 
signiﬁ  cant up-regulation of nestin (Figure 4b), whereas 
a single intravitreal injection of 50 μg/mL LPS led to a 
signiﬁ  cant up-regulation of nestin (p  0.05). Nestin was 
not further up-regulated by a single intravitreal injection 
of a combination of 5 nmol soluble Aβ1–42 and 50 μg/mL 
LPS (Figure 4b). However, the up-regulation of nestin in 
response to the higher dose of LPS was already close to 
maximal, so masking any additional and/or synergistic effect 
that might be caused by combining 50 μg/mL with 5 nmol 
Aβ1–42. A similar pattern was evident when comparing the Clinical Ophthalmology 2008:2(4) 808
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nestin response of a combination of aggregated (4 days) 
Aβ plus LPS (50 μg/mL) injected subretinally with that 
of aggregated (4 days) Aβ1–42 injected subretinally (results 
not shown). The fact that injection of LPS causes a similar 
up-regulation in retinal macroglial nestin-IR to that produced 
by Aβ1–42 indicates that this up-regulation is likely to be a 
generalized stress response.
B. 30-day exposure
Nestin was still signiﬁ  cantly up-regulated (p  0.05) 
30 days after a single intravitreal injection of aggregated 
(8 days) Aβ1–42 (5 nmol), though this was very signiﬁ  cantly 
reduced response (p  0.01) when compared to the nestin 
up-regulation 2 days after this injection (Figure 4c). Thus, 
a single injection of aggregated AB1–42 has profound 
long-term effects on retinal Müller cells, even 1 month 
later.
GFAP
GFAP forms a major component of astrocytic intermediate 
ﬁ  bres, and within the retina it is only expressed in astocytes 
and Müller cells. Müller cells tend to increase GFAP 
expression in response to focal or generalized injury. Growth 
factors are known to affect GFAP expression. For instance, an 
intravitreal injection of basic ﬁ  broblast growth factor (bFGF) 
leads to an increase in GFAP-IR in Müller cells of normal 
eyes (Lewis et al 1992), whereas an intravitreal injection of 
brain derived neurotrophic factor (BDNF) causes a decrease 
in GFAP expression in a feline model of retinal detachment 
(Lewis and Fisher 1997).
A. 2-day exposure
(i) Effect of length of pre-injection incubation time
Although visually, GFAP appeared to be up-regulated by 
a single injection of aggr Aβ1–42 iv (Figure 2), this was not 
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Figure 4 Retinal nestin response to (a) a single injection of 5nmol/3 μl soluble Aβ1–42, aggregated (4d) Aβ1–42, aggregated (8d) delivered either intravitreally or subretinally; 
(b) a single intravitreal injection of 10 μg/mL LPS, 50 μg/mL LPS, soluble Aβ1–42 and a combination of 50 μg/mL LPS and soluble Aβ1–42; (c) 2 days and 30 days after a single 
injection of aggregated (8d) Aβ1–42; (d) a single intravitreal injection of aggregated (8d) Aβ1–42 derived from California Peptide and from Bachem for comparison. Score values 
are represented as Mean ± SEM. Levels of statistical signiﬁ  cance are: *p  0.05; **p  0.01.Clinical Ophthalmology 2008:2(4) 809
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found to be statistically signiﬁ  cant (Figure 5a). The greatest 
GFAP response was found with a single intravitreal injec-
tion of 8-day pre-aggregated Aβ1–42 (compare Figure 3b 
with Figure 2). The difference in GFAP response between 
aggregated (8 days) Aβ1–42 and PBS was very signiﬁ  cant at 
a P value  0.01 (Figure 5a). This was also the signiﬁ  cance 
level of the difference between aggregated (8 days) Aβ1–42 
(5 nmol/3 μL) and aggregated (4 days) Aβ1–42 (5 nmol/3 μL) 
(Figure 5a). The response to aggregated (4 days) Reverse 
Aβ42–1 (5 nM/3 μL) did not signiﬁ  cantly differ from PBS 
alone (Figure 5a). There was no signiﬁ  cant difference in 
GFAP-IR response between intravitreal soluble Aβ1–42 and 
intravitreal aggregated (4 days) Aβ (Figure 5a).
(ii) Source of Aβ1–42
Unlike nestin, the GFAP up-regulation to a single intravitreal 
injection of aggregated (8 days) Aβ1–42 (5 nmol/3 μL PBS) from 
California Peptide was signiﬁ  cantly greater than the equivalent 
sourced from Bachem (Figure 5d). This suggests that different 
sources of Aβ may have signiﬁ  cantly different effects on some 
cellular markers while others seem to be unaffected.
(iii) LPS
GFAP was only signiﬁ  cantly up-regulated (p  0.05) in 
10 μg/mL LPS (Figure 5b). Treatments with 50 μg/mL 
LPS or 50 ug/mL LPS plus soluble Aβ1–42 (5 nM) failed 
to signiﬁ  cantly up-regulate GFAP. Again, this reﬂ  ects the 
weaker, more ﬁ  ckle nature of GFAP-IR expression in the 
retina when exposed to soluble Aβ1–42 and aggregated (4 days) 
Aβ1–42 compared to the much stronger expression in those 
retinas exposed to aggregated (8 days) Aβ1–42.
B. 30-day exposure
Up-regulation of GFAP after an Aβ1–42 exposure time 
of 2 days was very significant (p  0.01) for GFAP 
(Figure 5c). Compare this with a signiﬁ  cance level of 
p  0.05 for nestin. GFAP up-regulation fell signiﬁ  cantly 
at 1 month post-injection (p  0.05, see Figure 5c). Nestin 
up-regulation also fell signiﬁ  cantly (p  0.05) from that at 
2 days to that at 30 days (Figure 4c). In spite of this general 
fall in nestin expression, focal up-regulation of nestin was 
observed in short segments of retina localized with regions 
of remaining choline acetyl transferase (ChAT) expression 
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Figure 5 Retinal GFAP response to (a) a single injection of 5nmol/3 μl soluble Aβ1–42, aggregated (4d) Aβ1–42, aggregated (8d) delivered either intravitreally or subretinally; 
(b) a single intravitreal injection of 10 μg/mL LPS, 50 μg/mL LPS, soluble Aβ1–42 and a combination of 50 μg/mL LPS and soluble Aβ1–42; (c) 2 days and 30 days after a single 
injection of aggregated (8d) Aβ1–42; (d) a single intravitreal injection of aggregated (8d) Aβ1–42 derived from California Peptide and from Bachem for comparison. Score values 
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(Watts et al 2008, in preparation). Since Müller glia 
provide functional support to retinal neurons, the sustained 
induction of nestin and GFAP may be speciﬁ  cally involved 
in neuroprotective efforts.
Injection of Aβ results in some minor up-regulation of 
GFAP and nestin in the contralateral eye. This could be the 
result of the treated eye releasing blood-borne cytokines into 
the bloodstream. However, the extent of this contralateral effect 
tends not to vary signiﬁ  cantly with different treatments.
Nestin-IR responses failed to show signiﬁ  cant differences 
in the three separate experiments where 4-day pre-aggregated 
Aβ1–42 was injected intravitreally (results not shown). Thus, 
the inter-experimental variation of our model was not 
signiﬁ  cant.
Effects of Aβ1–42 on VEGF, VEGF-IR 
and albumin
There is experimental evidence that Aβ1-42 has profound 
effects on the cerebral vasculature. Aβ constricted isolated 
aortas and signiﬁ  cantly reduced the vasodilatory effect 
of acetylcholine (Thomas et al 1996). Transgenic mice 
over-expressing APP exhibited a selective impairment in 
endothelium-dependent regulation of cerebral blood ﬂ  ow 
which was not detected when superoxide dismutase was 
applied topically to the cerebral cortex or in transgenic 
mice expressing both APP and superoxide dismutase-1 
(Iadecola et al 1999). We decided to test whether treatment 
with Aβ 1–42 opens the BRB. Treated eyes received a single 
intravitreal injection of Aβ1–42 and their retinas were tested 
for the expression of VEGF, VEGF-R1 and for any indication 
of extravascular leakage of albumin at 2 and 5 days after 
injection.
Immunoﬂ  uorescent co-staining of retinal vasculature and 
blood-borne albumin associated proteins was conducted to 
provide novel information on the effects of Aβ1–42 on vascular 
integrity and how this may contribute to the neuropatho-
logical sequelae of Alzheimer’s disease. We investigated 
the effect of Aβ1–42 on expression of vascular endothelial 
growth factor (VEGF), VEGF-receptor type 1 (VEGF-R1) 
and the presence of blood-borne albumin within the retinal 
parenchyma as evidence of as evidence of vascular leakage. 
The leakage of albumin was investigated in 20 μm retinal 
sections 48 hours after injection of Aβ1–42 and in retinal 
ﬂ  atmounts 5 days after intravitreal injection of Aβ1–42.
VEGF
VEGF is expressed most intensely in the GCL, but is also 
expressed in cells of the INL (Figure 6a, non-injected). 
A single intravitreal injection of aggregated Aβ1–42 (5 nM) 
showed a marked up-regulation of VEGF after 2 days expo-
sure, particularly in the GCL, with weaker up-regulation on 
the inner and outer borders of the INL as well as a thin band in 
the photoreceptor layer (Figure 6a, injected). There was also 
scattered VEGF staining in the choroidal sheath behind the 
retina in both injected and non-injected eyes (Figure 6a).
VEGF-R1
VEGF-R1 (Flt-1) is expressed mainly in the GCL, 
INL (Figure 6b, non-injected). VEGF-R1 was strongly 
up-regulated 2 days after a single intravitreal injection of 
soluble Aβ1–42 (Figure 6b, injected). This up-regulation 
was particularly strong within the GCL, INL, with strong, 
extensive VEGF-R1- IR in Müller cell processes. However, 
eyes receiving a single intravitreal injection of aggregated 
Aβ42–1 (reverse peptide) showed no change in VEGF 
expression between injected and non-injected eyes (results 
not shown).
Albumin
A single intravitreal injection of aggregated (8-day) Aβ1–42 
resulted in leakage of albumin from many of the retinal 
blood vessels after an exposure time of 2 days (Figure 6c, 
injected), manifesting itself as strongly staining zones of 
albumin immunoreactivity in the retinal parenchyma imme-
diately surrounding the blood vessels. Albumin leakage was 
particularly prevalent in the OPL, those on the INL-IPL 
border between the IP (Figure 6c, injected). The contralateral 
eyes showed little or no albumin leakage (Figure 6c, 
non-injected).
Confocal microscopy of the ﬂ  atmounts (Figure 7) also 
showed the presence of extravascular albumin in those retinas 
exposed to Aβ1–42, thus conﬁ  rming the enhanced leakiness of 
the BRB, presumably through the opening of the intercellular 
tight junctions.
Discussion
Aβ1–42 enhances glial nestin-IR and GFAP-IR
Though we saw no evidence of pyknosis or TUNEL staining 
after the 48-hour exposure period, the signiﬁ  cant thinning of 
the retina 30 days after injection of Aβ1–42 provides evidence 
that signiﬁ  cant neural cell death occurred (Watts et al 2008, 
in preparation). This implies that neural cell death occurred 
subsequent to the 48-hour window. This requires further 
investigation.
Since a single intravitreal injection of aggregated (8 days) 
Aβ1–42 signiﬁ  cantly increased retinal nestin-IR (p  0.05, Clinical Ophthalmology 2008:2(4) 811
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Figure 4a) and GFAP-IR (p  0.01, Figure 5a) compared to 
their responses to a single intravitreal injection of aggregated 
(4 days) Aβ1–42 and soluble Aβ1–42 (p  0.05 in the case of 
nestin, Figure 4a), this implies that the aggregation state of 
Aβ plays an important active role in Aβ-induced pathology, 
assuming that incubation of Aβ at 37 °C encourages 
aggregation. Unfortunately, our laboratory had no facilities 
to investigate the actual aggregation state of the Aβ sources 
injected intraocularly. However, it was found that the 
Aβ source became more viscous when incubated at 37 °C for 
4 days and 8 days. Certainly, the nestin response is found to 
increase with the length of pre-injection incubation time at 
37 °C. This evidence would appear to raise the importance 
of the aggregated form of Aβ over that of soluble Aβ since 
the most aggregated form (ie, Aβ pre-aggregated for 8 days) 
maximized the nestin and GFAP response. This is not to 
suggest that Aβ monomers and oligomers are not toxic to the 
neural retina, since they could be toxic in different ways to 
that of aggregated Aβ. Recent opinion suggests that soluble 
Aβ oligomers (ADDLs) rapidly inhibit long-term potentia-
tion and reversal of long-term depression, resulting in a loss 
of synaptic plasticity which may explain the memory loss in 
patients in the early stages of AD (Klein 2006). However, 
aggregated deposits of Aβ may act as reservoirs of potentially 
soluble oligomers as a consequence of the equilibrium that 
exists between soluble and aggregated Aβ.
Synaptic strength in the intact retina is regulated by 
astrocytes (Newman and Zahs 1998). Also, Müller cell 
processes are present in most layers of the retina and are the 
primary cells involved in the removal of glutamate from the 
Non-injected Injected
(b) VEGF-R1
(a) VEGF
(c) Albumin
Figure 6 The response of (a) VEGF (DAB), (b) VEGF-R1 (red) and (c) albumin (red) 48 hours after a single intravitreal injection of aggregated Aβ1–42. Blood vessels are represented 
in green and cell nuclei in blue. (a) VEGF immunoreactivity is up-regulated by the Aβ1–42 injection, particularly in the GCL and within the inner and outer boundaries of the 
INL. (b) VEGF-R1 immunoreactivity increases in GCL, INL and in the Müller cell processes (white arrows), but not in the ONL. (c) Albumin leaks from the vasculature of the 
injected eye, but this is not the case in the contralateral non-injected eye. Note that albumin only appears in the vicinity of the retinal microvasculature. Scale bar, 100 μm in 
(a) and 50 μm in (b) and (c).
Abbreviations: gcl, ganglion cell layer; inl, inner nuclear layer; onl, outer nuclear layer.Clinical Ophthalmology 2008:2(4) 812
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synaptic cleft. Müller cells express a high afﬁ  nity glutamate 
transport system (Bouvier et al 1992) and high levels of gluta-
mine synthetase (Riepe and Norenberg 1977). Indeed, retinal 
neuronal cell bodies are enveloped by basket-shaped Müller 
cell lamellae, while their synapses that lie within the IPL and 
OPL are surrounded by further processes of the adjacent 
Müller cells (Ramussen 1972; Uga and Smelser 1973). 
We have found that glial cells form basket-like structures 
around neural somata in the GCL (results not shown). 
However, this is not the case in all species. For example, 
in retinal capillary layer 1 (lying between the OPL and the 
INL) of the tree shrew (Tupaia belangeri) 46.8 ± 15.3% 
(mean ± SEM) of the relative surface of capillary basal 
lamina is ensheathed with neuronal horizontal cells 
(Ochs et al 2000); thus supporting the hypothesis that 
horizontal cells represent a cell type intermediate between 
neuronal and glial cells.
In summary, what is particularly interesting in terms 
of nestin is that the model shows a graded response to our 
different treatments where the 8-day response  the 4-day 
response  4-day response to the reverse peptide (Aβ42–1) 
(Figure 4a). The Aβ42–1 response was no greater than the 
response to PBS, which reﬂ  ects its status as a non-functional 
control peptide and demonstrates that Aβ1–42 exerts speciﬁ  c 
effects on nestin expression (Figure 4a). Therefore, nestin 
appears to provide an excellent index of pathological glial 
response to Aβ exposure. It also indicates that the degree 
of Aβ aggregation is important for maximizing the nestin 
response in our model.
The effects of Aβ on retinal GFAP up-regulation reported 
in this paper conﬁ  rm and reﬁ  ne previous results reported by 
Walsh et al (2005) who found a marked increase in GFAP 
immunoreactivity in the radial processes of Müller glial cells. 
Here we have further determined the graded GFAP responses 
to different doses of Aβ, different aggregation states, and 
different injection sites within the eye (ie, intravitreal and 
subretinal). Like nestin, GFAP response was strongest when 
Aβ1–42 was incubated at 37 °C for 8 days prior to injection 
into the eye. However, GFAP-IR in the Müller cell radial 
processes was not as heavy as that of nestin. That our results 
showed that aggr (4 days) Aβ1–42 iv failed to signiﬁ  cantly 
up-regulate GFAP-IR contrasts with previous evidence 
produced in this laboratory (Walsh et al 2005). This might be 
because of changes in the manufacturing methods at source 
which render the product less aggregatory so that modern 
sources require longer pre-injection aggregation periods.
Nestin-positive cells tend to be conﬁ  ned to the pigmented 
ciliary bodies of the normal adult retina (Ahmad et al 2000; 
Tropepe et al 2000). Early research found that nestin-IR was 
absent from astocytes and Müller cells in retinal ﬂ  at-mounts 
and was only detectable in neural stem cells (Xue et al 
2006). However, one week after the experimental induction 
Non-injected injected
Figure 7 Aβ induces leakage of albumin from the retinal vasculature. Confocal images of retinal ﬂ  atmounts of blood vessels labelled with antibody to RECA-1 (green) and 
albumin labelled with antibody raised against albumin (red). Note that the control (left) exhibits little or no albumin leakage, whereas the retina injected with Aβ1–42 (right) 
exhibits localized leakage around several blood vessels.Clinical Ophthalmology 2008:2(4) 813
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of glaucoma, GFAP-IR was increased in the end-feet of 
Müller cells, and nestin-IR was increased in the end-feet 
of Müller cells and in some astrocytes (Xue et al 2006). 
Intraocular injection of NMDA induces an increase in the 
expression of transitin, a nestin-related intermediate ﬁ  lament 
in the chicken Müller glia in the chicken retina (Fischer and 
Omar 2005). Nestin expression in Müller cells has also been 
induced by laser injury (Kohno et al 2005). Glial cell nestin 
expression appears to be a marker for injury in general. This is 
conﬁ  rmed by our study where Aβ induced nestin expression 
in Müller cells.
Two types of reactive gliosis have been identiﬁ  ed in 
neural tissue: one type supports neuritic extension and 
those that inhibit it (Sivron and Schwarz 1995). Permis-
sive gliotic scars contain signiﬁ  cantly less gap junctions 
than inhibitory gliotic scars (Alonso and Privat 1993). 
Reactive astrocytes are capable of expressing nestin alone, 
GFAP alone, or transiently co-expressing both GFAP and 
nestin in response to neural injury (Krum and Rosenstein 
1999). These researchers found that many of the nestin-
positive reactive astrocytes were situated in the vicinity 
of blood vessels; indeed, 7% of astrocytes presented with 
colocalization of nestin and VEGF, and 25% of astrocytes 
presented with colocalization of nestin with VEGF-R1 
(Flt-1). Krum and Rosenstein (1999) further showed that 
this nestin up-regulation following brain injury correlated 
temporally with angiogenesis and the loss of blood-brain 
barrier properties.
In this paper, we present evidence which parallels retinal 
responses to injury with that in the brain reported by Krum 
and Rosenstein (1999). VEGF itself has been shown to have 
proliferative effects on astroglia (Silverman et al 1999). 
We have found that intravitreal injection of aggregated Aβ1–42 
induces up-regulation of both nestin and VEGF-R1 in Müller 
glia cells and that this coincides with leakage of albumin 
from the vasculature. Although Krum and Rosenstein (1999) 
found that nestin expression peaked at 7–10 days postopera-
tive brain trauma and was absent by 28 days, we found that 
retinal nestin expression in Müller cells remained strong 
even 1 month after a single injection of aggregated Aβ1–42. 
This is not surprising since the source of injury (the Aβ1–42 
bolus) will persist in the enclosed vitreous humor adjacent 
to the retina. Concerning this persistent source of injury, 
Weldon et al (1998) found that ﬁ  brillar Aβ persisted in the 
rat striatum for at least 30 days after injection, whereas the 
soluble form of Aβ was cleared within 1 day.
Aβ1–42 peptide with a known potency established in all 
our 2-day exposure experiments (ie, California Peptide) was 
compared with Aβ1–42 obtained from a different manufacturer 
(Bachem). The peptides were prepared in an identical manner 
(5 nmol in 3 μL, 8-day aggregation period) and examined 
after 1-month survival (Figure 4d and Figure 5d). Although 
no differences were seen for nestin induction, GFAP 
up-regulation was signiﬁ  cantly greater among California 
Peptide injected eyes than for Bachem (p  0.05).
There is evidence that nestin appears to act as a 
survival factor, particularly in neurons, and perhaps this 
also applies to glial cells such as Müller glia. Intermediate 
ﬁ  bres function as scaffolds for the organization of intracel-
lular kinases. For instance, cytoplasmic serine/threonine 
kinase, cyclin-dependent kinase 5 (Cdk5) is associated 
with nestin (Sahlgren et al 2003). Nestin is cytoprotective 
under conditions of oxidative stress (Sahlgren et al 2006). 
It has been suggested that nestin stabilizes the speciﬁ  c 
activator p35 and that cytoplasmic Cdk5 activity would 
have a cytoprotective inﬂ  uence, whereas an accumulation 
of nuclear Cdk5 would lead to cell death (O’Hare et al 
2005). The binding of Cdk5/p35 to the nestin scaffold 
prevents p25 formation, so preventing the formation of the 
toxic Cdk5/p25 complex.
Aβ1–42 opens the blood-retinal barrier
Our investigation of the effects of Aβ on the BRB provides 
in vivo support of in vitro studies initially conducted at GSK 
(Marco and Skaper 2006).
Capillary distortion, endothelial degeneration, BBB 
disruption, basal membrane thickening and perivascular 
neuroinﬂ  ammation are just some of the vascular abnormali-
ties found in patients with AD (Paris et al 2004). Smaller 
arteries suffer loss of smooth muscle along with intracerebral 
hemorrhaging owing to dilation and rupture (Greenberg 
et al 2004), while atherosclerotic plaques are a common 
feature in the larger blood vessels, leading to microin-
farctions and hypoperfusion (Casserly and Topol 2004). 
Neurovascular coupling is also compromised in AD patients 
and in AD models (Tanako et al 2007), and Aβ plaques are 
preceded by a drop in vascular density in AD mouse models 
(Niwa et al 2002).
VEGF has many functions, which include: endothelial 
survival; stimulating angiogenesis; enhancement of vascular 
permeability; neurogenesis and neuroprotection. Binding of 
VEGF to the VGFR2 receptor activates neuronal survival 
pathways. Indeed transgenic neuronal overexpression 
of VEGFR2 protects the motor neurons of ALS mice 
(Storkebaum et al 2005). VEGF promotes neurite exten-
sion, modulates synaptic activity and improves memory Clinical Ophthalmology 2008:2(4) 814
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and cognition. VEGF also supports muscle cell regeneration 
and stimulates the proliferation and migration of Schwann 
cells, thus promoting the remyelination of axons (Zacchigna 
et al 2008).
VEGF is up-regulated in response to hypoxia when 
hypoxia-inducible factors bind to a hypoxia response element 
in the promoter of the VEFG gene (Carmeliet 2000). Mice 
with a deletion in the hypoxia response element developed 
amyotrophic lateral sclerosis (ALS)-like progressive 
motor-neuron degeneration (Oosthuyse et al 2001). 
Intracerebroventricular administration of recombinant VEGF 
to a SOD1(G93A) rat model of ALS delayed paralysis by 
17 days, improved motor function and increased life span 
by 22 days (Storkebaum et al 2005). Our results on the 
distribution of VEGF-IR in the retina reﬂ  ects that reported 
by Zhang et al (2004), who showed that VEGF staining 
occurred in the inner limiting membrane, GCL, INL, with 
weaker staining in the outer limiting membrane and retinal 
pigment epithelium.
VEGF dampens glutamatergic transmission during 
epileptic discharges (McCloskey et al 2005) and directly 
protects neurons against hypoxic stress by enhancing 
the tyrosine phosphorylation of the potassium channel 
Kv1.2, which prevents it from becoming over-active 
(Qui et al 2003). It has been suggested that VEGF gets 
sequestered in amyloid plaques, thus reducing the former’s 
neuroprotective inﬂ  uence (Yang et al 2004). The intra-
vitreal injection of a VEGF inhibitor leads to reduction 
in retinal ganglion cells, while administration of VEGF 
protects ischemic retinal neurons against apoptosis 
(Nishijima et al 2007).
VEGF-R1 tends to be expressed most abundantly on 
glial cells, whereas VEGF-R2 (Flk-1/KDR) is expressed 
most abundantly on neurons (Lambrechts et al 2003; 
Storkebaum et al 2005). VEGFR2, not VEGFR1, appears 
to be essential for the neuroprotective action of VEGF in 
the retina (Nishijima et al 2007). These workers found that 
VEGFR2 was highly expressed in vascular endothelial cells 
and in neuronal cells in the GCL and INL after ischemia, 
whereas photoreceptors in the ONL were VEGFR2-negative. 
Nishijima et al (2007) suggested that this might be the reason 
why VEGF treatment failed to rescue neural cells from cell 
death within the ONL in contrast to its neuroprotective effects 
within the GCL and INL.
The effects of VEGF on the integrity of the BBB appear 
to be dose-dependent. Low levels of VEGF are necessary 
to maintain the integrity of the quiescent endothelial 
cells, whereas very high levels of VEGF increase BBB 
permeability, as has been reported in severe cerebral ischemia 
and in epilepsy (Croll et al 2004; Nico et al 2007).
What is particularly interesting is that not only did a 
single intravitreal injection of aggregated (8 days) Aβ1–42 
enhance VEGF-IR, there was also a marked up-regula-
tion of VEGFR1-IR in the GCL and ICL as well as the 
processes of the Müller glia (Figure 6b, injected). Perhaps 
the up-regulation in VEGFR1-IR in the processes of Mül-
ler glia, is “glioprotective: since Müller cells appear to 
survive exposure to Aβ1–42. The expression of VEGFR1 
also appears increased in the vasculature of the retina. This 
might explain the leakage of albumin inform the retinal 
blood vessels in the injected eye when compared with that 
of the non-injected eye (Figure 6c). Like VEGFR2, we 
found that VEGFR1 is not expressed in the ONL. As was 
the case with the 2-day exposure to aggregated (8 days) 
Aβ1–42, a 5-day exposure resulted in albumin leakage in the 
injected eye (Figure 7).
The relationship between retinal GFAP expression and 
the integrity of the BRB (measured using Evan’s blue) 
has been investigated in streptozotocin (STZ)-diabetic 
rats (Ma et al 2007). These researchers found that GFAP 
expression was restricted to nerve ﬁ  bre layer (NFL) and GCL 
of normal retinas. Within 1 month of the onset of diabetes, 
GFAP-IR was increased in the NFL and GCL. By 3 and 
6 months, GFAP-IR had increased in Müller cells while 
occludin (a protein present in the tight junctions between 
vascular endothelial cells) had progressively decreased, the 
latter being reﬂ  ected by incremental increases in leakage of 
Evan’s blue across the BRB. It was concluded that while 
the reactive astrocytes in the retina helped maintain BRB 
integrity, the activation of Müller cells compromised BRB 
integrity. Our results also appear to support their hypothesis 
since we found albumin leakage into the retinal parenchyma 
along with GFAP up-regulation in Müller cells in eyes 
injected with Aβ1–42. There is also evidence that Aβ1–42 is 
angiogenic (Boscolo et al 2007).
The Institute of Ophthalmogy has recently shown that 
there is a connection between glaucoma and Aβ. This renders 
the discoveries of Xue et al (2006) particularly apposite to 
those reported in this paper. Interestingly, caspase 3 has 
been shown to colocalize with GFAP in the glaucomatous 
retina (Wang et al 2005). Also, in the context of age-related 
macular degeneration (AMD), it has also been demonstrated 
that Aβ caused increased VEGF expression in retinal pigment 
cells (Yoshida et al 2005).
The rat retinal injection model described in this paper 
could be a valuable tool in investigating mechanisms of Clinical Ophthalmology 2008:2(4) 815
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Aβ-induced toxicity in diseases such as Alzheimer’s disease 
and AMD.
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